Journalists and other readers should disregard the news release "Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository" OTC:ORMP, issued earlier today. The release was transmitted in error by PR Newswire. DATASOURCE: Oramed Pharmaceuticals Inc. CONTACT: Company and Investor Relation Contacts: Oramed Pharmaceuticals, Eric Rosenberg, Cell: +972-54-566-7713, Office: +972-2-566-0001, Email: ; Media Contacts: Ruder Finn Israel for Oramed, Matthew Krieger, Cell: +972-54-467-6950, Office: +972-2-589-2003, Email:

Copyright